• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Novartis' asthma triplet beats GSK's Advair in phase 2 trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 22, 2019 at 10:52: AM
via Novartis’ triple combination asthma candidate QVM149 has beaten GlaxoSmithKline’s Advair in a phase 2 trial. The study linked QVM149 to statistically significant improvements in lung function, leading Novartis to talk up its potential to improve outcomes in uncontrolled asthma.

article source
 

<



Similar threads

cafead
Novartis&#039; asthma drug fails in phase 3, raising doubts about Gossamer&#039;s prospects
Replies
1
Views
181
Pharma/Biotech Companies - In the News
Woody
cafead
Upcoming events – Novartis’s asthma Zeal and Alnylam&#039;s lumasiran test
Replies
0
Views
141
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Despite trial scare, Travere&#039;s Filspari gains full FDA nod in kidney disease showdown with Novartis
Replies
0
Views
30
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis&#039; Complement Inhibitor Fabhalta Approved for IgAN
Replies
0
Views
50
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves Novartis&#039; kidney disease drug
Replies
0
Views
51
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote